FDA Approves Belimumab for Patients Aged 5 With Systemic Lupus Erythematosus
Pharmacy Times
MAY 20, 2024
Belimumab (Benlysta; GSK) is a B-lymphocyte stimulator-specific inhibiting monoclonal antibody.
Mon.May 20, 2024
167 
Post COVID-19 Condition: The Frustrating Fight for Recognition and Treatment
Drug Topics
MAY 20, 2024
Health care providers must listen to patients who voice their experiences with post–COVID-19 condition symptoms. Only then can a clearer picture of the condition emerge for the millions of patients who have the near-invisible disease.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Health Care Shortage Calls for Diversifying the Role of Community Pharmacists in Treatment of Minor Ailments
Pharmacy Times
MAY 20, 2024
New research study reveals the potential of community pharmacists for minor ailment treatment, allowing for diversified patient care during growing health care shortage.
STAT+: AI & drug discovery: A biotech CEO, a scientist, and a venture capitalist separate hype from reality
STAT
MAY 20, 2024
Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing. To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
FDA Approves First Biosimilars to Eylea
Pharmacy Times
MAY 20, 2024
Aflibercept-jbvf (Yesafili; Biocon Biologics) and aflibercept-yszy (Opuviz; Biogen) are the first interchangeable biosimilars to aflibercept (Eylea; Regeneron).
STAT+: PBM executives invited to testify before House panel
STAT
MAY 20, 2024
WASHINGTON — Executives from the three major pharmacy benefit manager companies have been invited to testify before the House Committee on Oversight and Accountability next month, four sources familiar with the planning told STAT. Executives from Optum, CVS Caremark, and Express Scripts, owned by Cigna, were asked to testify before the panel on June 4.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
STAT+: Medical crowdfunding isn’t a solution for skyrocketing health care costs
STAT
MAY 20, 2024
In the United States, health care costs are so out of control that medical crowdfunding has become commonplace. The idea is simple: turn your social network into a financial safety net to cover the cost of expensive treatments or long illnesses. Millions of Americans have started crowdfunding campaigns for medical bills, and tens of millions have donated to them, mostly through the undisputed sector leader, GoFundMe.
Safe Storage Is the Cornerstone of Medication Safety
Pharmacy Times
MAY 20, 2024
Many factors must be considered when stocking new deliveries
STAT+: BIO to announce reorganization, senior leaders expected to depart
STAT
MAY 20, 2024
WASHINGTON — The Biotechnology Innovation Organization on Monday is announcing a significant restructuring accompanied by a shakeup, according to five sources familiar with the planning. A few senior leaders are expected to depart as part of the reorganization.
Study Results Find Mood and Sleep Disorders Negatively Impact Asthma Control
Pharmacy Times
MAY 20, 2024
Despite the finding, the authors suggest further research is done to better understand the mechanisms behind the interactions between asthma, sleep, and depression.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT+: Bernie Sanders may have reached the limits of his pharma pressure campaign
STAT
MAY 20, 2024
WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him. For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’
FDA Approves Self-Collection cobas HPV Test for Early Detection of Cervical Cancer Early
Pharmacy Times
MAY 20, 2024
In 2014, the cobas human papillomavirus test was approved by the FDA for first-line, primary screening in women aged 25 years and older.
Hims & Hers expands weight loss program to include access to GLP-1 medications
Fierce Healthcare
MAY 20, 2024
Six months after launching its weight loss program, online health and wellness company Hims & Hers added compounded GLP-1 medications to its offerings. | Six months after launching its weight loss program, online health and wellness company Hims & Hers added compounded GLP-1 medications to its offerings.
Preparing for Success: Tips on How to Excel on Your IPPE Rotations
Pharmacy Times
MAY 20, 2024
Five tips to keep in mind before you begin your IPPEs.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
HHS' ARPA-H offering more than $50M for hospital cybersecurity platform pitches
Fierce Healthcare
MAY 20, 2024
The Department of Health and Human Services’ (HHS’) research funding agency is floating more than $50 million to developers who can build a scalable cybersecurity platform able to keep hospitals' c | The UPGRADE program will be handing out millions to those with the best pitches on how to detect hospital cybersecurity weaknesses and deploy fixes with minimal interruptions to care delivery.
As Stelara nears patent cliff, J&J fortifies Tremfya for upcoming ulcerative colitis showdown
Fierce Pharma
MAY 20, 2024
The biologics market for inflammatory bowel disease is continually getting more competitive, and now Johnson & Johnson’s Tremfya is the latest medicine angling to make a mark in the space. | The biologics market for inflammatory bowel disease is continually getting more competitive, and now Johnson & Johnson’s Tremfya is the latest medicine angling to make a mark in the space.
Final report says UK infected blood scandal “should have been avoided”
Pharmaceutical Technology
MAY 20, 2024
Nearly 30,000 people, including children in clinical trials, were infected with hepatitis C and HIV from contaminated blood products in the 1970s and 1980s.
Pfizer unit wins $107.5M verdict in cancer-drug patent case against AstraZeneca
Fierce Pharma
MAY 20, 2024
A Delaware federal jury has ordered AstraZeneca to fork over $107.5 million to Pfizer for infringing two of the latter company's patents with its marketing of blockbuster oncology med Tagrisso. | Pfizer's Wyeth subsidiary and licensee Puma Biotechnology sued AstraZeneca in 2021 for alleged patent infringement related to AZ's marketing of cancer blockbuster Tagrisso.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Unlocking biotech insights: Top 10 podcasts you need to listen to
pharmaphorum
MAY 20, 2024
Unlocking biotech insights: discover the latest advancements in biotech with our top picks for podcasts. Stay informed and up-to-date with industry trends and news by listening to some of the best biotech podcasts featuring expert analysis, discussions of ethical issues, and interviews with industry leaders.
Why patient-centricity is essential to accelerate rare disease clinical research
European Pharmaceutical Review
MAY 20, 2024
Rare diseases affect up to 36 million people in the EU, and as many as 400 million people globally. 1,2 they are often progressive, life-limiting and incurable. Half of people diagnosed with a rare disease are children, 30 percent of whom die before they reach the age of five. 3 Significant unmet needs The path to diagnosis of a rare disease is complex, taking on average five to eight years from the onset of symptoms before a patient receives an accurate diagnosis. 4 In some countries, limited a
Lab at center of Zantac saga claims GSK hid drug’s risks for decades
Fierce Pharma
MAY 20, 2024
Even as GSK defends itself against thousands of personal injury lawsuits relating to its sale of heartburn pill Zantac, a whistleblower lawsuit from the laboratory that first raised alarm bell | A newly unsealed complaint from the laboratory that first revealed Zantac's links to a carcinogenic impurity lays out a web of allegations about GSK's efforts to bring the drug to market in the 1980s and its attempts to hide the risks since then.
Why AlphaFold 3 is stirring up so much buzz in pharma
PharmaVoice
MAY 20, 2024
The “Nobel Prize-worthy invention” could be worth hundreds of billions commercially — and have a deep impact on drug R&D.
STAT+: A novel spinal cord stimulator treats paralysis without surgery. FDA will rule on it soon
STAT
MAY 20, 2024
After his spinal cord injury in 2014, Sherown Campbell worked hard to regain as much bodily function as he could. Once a dedicated athlete, Campbell had to learn the new limits of his body. One of them, jarringly, was his body’s inability to sweat. So when Campbell started sweating on his stationary bike for the first time in seven years, it felt surreal.
Sanofi and Regeneron update trial data, strengthening case for Dupixent in COPD
Fierce Pharma
MAY 20, 2024
At the American Thoracic Society international conference in San Diego, one of the major themes is the advance of new therapies for chronic obstructive pulmonary disease (COPD). | At the American Thoracic Society international conference, one of the major themes is the advance of new therapies for COPD. On Monday, Sanofi and Regeneron had their answer to Amgen and AstraZeneca's presentation from the day before.
PDURS explained: The FDA’s new framework for adding software to drug labels
pharmaphorum
MAY 20, 2024
In this fireside chat webinar, experts break down the FDA's new PDURS framework for adding software to drug labels. Learn how it impacts pharma and what you need to know. Join us on Tuesday 9th July @ 07:00am PDT / 10:00am EDT / 15:00pm BST / 16:00pm CEST.
AstraZeneca places $1.5B bet on end-to-end ADC manufacturing in Singapore
Fierce Pharma
MAY 20, 2024
Riding high on its Daiichi Sankyo-partnered antibody drug conjugate (ADC) Enhertu—and banking on an approval for its next ADC contender datopotamab durextecan this winter—AstraZeneca is placing a b | Riding high on its Daiichi Sankyo-partnered antibody drug conjugate (ADC) Enhertu—and banking on an approval for its next ADC contender datopotamab durextecan this winter—AstraZeneca is placing a big bet on the cancer-fighting technology as it blueprints a massive manufacturing investment in Asia.
ATS: Amgen, AZ say data backs Tezspire’s role in COPD
pharmaphorum
MAY 20, 2024
Amgen and AstraZeneca have said their severe asthma therapy Tezspire could have a role to play in chronic obstructive pulmonary disease (COPD) – a key target indication for the drug – despite missing its primary objective in a clinical trial.
Semaglutide Reduces Weight, Truncal Fat In Patients With MASLD
Drug Topics
MAY 20, 2024
A poster presented at Digestive Disease Week showed that patients with MASLD taking semaglutide achieved significant weight loss while preserving skeletal muscle indices.
ATS: Vicore, Endeavor therapies show promise in IPF
pharmaphorum
MAY 20, 2024
Phase 2a data with drugs for idiopathic pulmonary fibrosis from Vicore and Endeavor raise hopes of disease-modifying therapy for the disease
Suicide is Second-Leading Cause of Death Among College Athletes
Drug Topics
MAY 20, 2024
Researchers examined the suicide rates of NCAA student-athletes from 2002 to 2022.
Novavax investor withdraws proxy fight after Sanofi deal
pharmaphorum
MAY 20, 2024
Shah Capital Management has withdrawn a proxy campaign against the re-election of director at vaccines firm Novavax in the wake of its $1.2 billion alliance with Sanofi. The top-three investor in Novavax – which has been steadily raising its stake in the company in recent weeks and now holds around 7.9% – said it welcomed the Sanofi deal but warned that “does not mean our engagement is at an end” and it still believes Novavax would benefit from a stockholder on its board of directors.
CGM Becoming Standard of Care in Hospital Settings
Drug Topics
MAY 20, 2024
Researchers analyzed the efficacy of continuous glucose monitoring as the standard of care for diabetes management in an inpatient setting.
Biotechs Rapport and Telix throw their hats into IPO ring
pharmaphorum
MAY 20, 2024
Biotechs Rapport and Telix throw their hats into IPO ring Phil.
Let's personalize your content